Re:

AvePoint, Inc.

Schedule TO-I filed August 27, 2024

File No. 005-91137

1.

Please ensure on future filings that the EDGAR tag “SC 13E-3/A” is associated with the filing, in addition to the EDGAR tag “SC TO-I/A.”

Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that the Company will ensure on future filings that the EDGAR tag “SC 13E-3/A” is associated with each filing, in addition to the EDGAR tag “SC TO-I/A.”

2.

Refer to your disclosure of “[a]lternatives: None” in Item 7(b) of the Schedule TO-I. Refer also to disclosure on page three of the Offer Letter that “[i]n evaluating the Transaction, the Company considered conducting an exchange offer for the Warrants as an alternative in which the Warrants would be exchanged for shares of Common Stock.” Given this apparent discrepancy, please revise or advise.

Response: The Company respectfully acknowledges the Staff’s comment and has amended and restated “(b). Alternatives” of “Item 7. Purposes, Alternatives, Reasons and Effects” of the Amended Tender Offer Statement accordingly.

3.

Disclosure in Item 9(c) states “[n]ot applicable.” Please revise and make the statements required by Item 1015(c) of Regulation M-A in the disclosure document.

Response: The Company respectfully acknowledges the Staff’s comment and has amended and restated “(c). Availability of documents” of “Item 9. Reports, Opinions, Appraisals and Negotiations” of the Amended Tender Offer Statement accordingly.

4.

Please provide the information required by Item 1003(c)(5) of Regulation M-A.

Response: The Company respectfully acknowledges the Staff’s comment and has amended Schedule I to the Offer to Purchase accordingly.

5.

We note the following disclosure on pages 3 and 26: "The foregoing conditions are solely for our benefit, and we may assert one or more of the conditions regardless of the circumstances giving rise to any such conditions." All offer conditions must be objective and outside the control of the offeror in order to avoid illusory offer concerns under Regulation 14E. Please revise the language relating to the circumstances that may "trigger" an offer condition to avoid the implication that they may be within the Company's control. See Question 101.02 of the Division of Corporation Finance's "Tender Offer Rules and Schedules" Compliance and Disclosure Interpretations.

Response: The Company respectfully acknowledges the Staff’s comment and has amended the disclosure on page 3 under the “Summary Term Sheet” of the Offer to Purchase and page 26 under “The Offer and Consent Solicitation, Section 10. Conditions; Termination; Waivers; Extensions; Amendments” of the Offer to Purchase” of the Offer to Purchase accordingly.

6.

We note your disclosure on page six that “[t]he Offer Purchase Price was determined following negotiations with parties holding more than a majority of the outstanding Warrants.” Describe such negotiations, including who initiated such negotiations. Refer to Item 1005(c)(2) of Regulation M-A, including the instruction thereto.

Response: The Company respectfully acknowledges the Staff’s comment and has amended the disclosure on page 1 under “Special Factors, Section 2. Fairness of the Transaction (Offer, Consent Solicitation and Redemption)” and page 6 under “Special Factors, Section 4. Effects of the Transaction on the Market for the Warrants” of the Offer to Purchase accordingly.

7.

Refer to disclosure on page 21 that you “estimate that the total amount of cash required to complete the Offer and Consent Solicitation, including the payment of any fees, expenses and other related amounts incurred in connection with the Offer and Consent Solicitation will be approximately $1,324,000 million” (emphasis added), which appears to be a typographical error. In addition, $1,324,000 appears to solely reflect the fees, expenses and other related amounts incurred in connection with the Offer and Consent Solicitation and does not include the amount required to purchase all of the outstanding Warrants. Please revise. 

Response: The Company respectfully acknowledges the Staff’s comment and has amended the disclosure on page 21 under “The Offer and Consent Solicitation, Section 6. Source and Amount of Funds; Fees and Expenses” of the Offer to Purchase accordingly.

cc:

Brian Michael Brown, AvePoint, Inc.

Justin A. Kisner, Cooley LLP